RE:Positive Recent events The lecanumab news is really great for PMN.
Significant results show benefit of the PMN310 mechanism.
12.5% ARIA-E with lecanumab justifies an alternative more specific approach- PMN310.
Dosing high is key for successful treatment. PMN310's selectivity will allow just that...
GLTA longs